title: PrEP implementation: moving from trials to policy and practice.
abstract: BACKGROUND
  It is increasingly clear that the HIV response will not be sustainable if the number of infections is not significantly reduced.
  
  
  CONCLUSIONS
  For two decades, research has been ongoing to identify new behavioural and biomedical strategies to prevent HIV infection. In the past few years, the efficacy of several new strategies has been demonstrated, including oral pre-exposure prophylaxis (PrEP; i.e. daily use of tenofovir/emtricitabine). Because several social, political and logistic barriers remain, however, optimal PrEP implementation will require a better dissemination of new evidence in a number of areas and additional implementation research from various disciplinary perspectives (i.e. social science, policy and ethics; health systems; and economics, including cost-effectiveness studies). Discussion of new evidence on those topics, as well as case studies of potential PrEP implementation in diverse environments, can improve the understanding of the role that PrEP may play in addressing the global HIV/AIDS epidemic.In light of these needs, the Network for Multidisciplinary Studies in ARV-based HIV Prevention (NEMUS) and the World Health Organization (WHO) were honoured to co-organize a special issue of JIAS aimed at contributing to a scholarly discussion of current conditions surrounding PrEP implementation, potential impact and efficiency, social science concerns and the study of PrEP implementation in specific country cases. The papers included in this monograph identify and cover many of the main aspects of the complex yet promising discussions around PrEP implementation today.
  
  
  CONCLUSIONS
  This is a collection of timely contributions from global leaders in HIV research and policy that addresses geographic diversity, uses a trans-disciplinary approach and covers a variety of the complex issues raised by PrEP. As this publication will become accessible to all, we hope that it will remain a valuable resource for policy makers, programme managers, researchers and activists around the world at a moment of a paradigm shift of the global response to HIV.
authors.affiliation: Center for Interdisciplinary Studies in Sexuality, AIDS and Society, Cayetano Heredia University, Lima, Peru; Carlos.caceres@upch.pe.
authors.forename: Carlos F
authors.initials: CF
authors.lastname: Cáceres
authors.affiliation: HIV Programme, World Health Organization, Geneva, Switzerland.
authors.forename: Kevin R
authors.initials: KR
authors.lastname: O'Reilly
authors.affiliation: Fenway Health, Beth Israel Deaconess Medical Center Boston, Harvard Medical School, Boston, MA, USA.
authors.forename: Kenneth H
authors.initials: KH
authors.lastname: Mayer
authors.affiliation: HIV Programme, World Health Organization, Geneva, Switzerland.
authors.forename: Rachel
authors.initials: R
authors.lastname: Baggaley
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D065129:Pre-Exposure Prophylaxis
chemical_list: D019380:Anti-HIV Agents
keywords: HIV; PrEP; implementation science; key populations; scale-up